Company: MDCXW
Filing Date: 2025-04-25
Form Type: DRS
Source: 0001062993-25-007956
Chunk: 171

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-25
Form: DRS
Chunk 171
---
)Includes 28,750 common shares underlying stock options that are currently exercisable.

(12)Includes 2,914,330 common shares held by Velocity Fund Partners, LP, an entity controlled by Dr. Kenneth R. Melani. Dr. Kenneth R. Melani's address is 1100 Stonegate Manor, Cheswick, PA 15024.

(13)Includes 2,000,000 common shares held of record by 215 Capital Togo PHL Fund I, LP. Ajay Raju's address is Two Liberty Place, 50 S. 16th Street, Suite 2710, Philadelphia, PA 19102.

(14)Includes 800,952 common shares held of record by SkinJect Partners LLC, an entity controlled by John Hathaway. John Hathaway's address is 285 Kappa Drive, Suite 100, Pittsburgh, PA 15238.

Based upon a review of the information provided to us by our transfer agent, as of April 15, 2025, there were 148 record holders of our common shares, one holder of record of our Public Warrants and one holder of record of our Regulation A Warrants. Such numbers do not include beneficial owners holding our securities through nominee names.

<div align='center'>116</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

<div align='center'>RELATED PARTY TRANSACTIONS</div>

The Company had an agreement with Velocity Fund Management, LLC ("VFM"), an affiliate of a shareholder of the Company, that provided for certain managerial positions to be filled from within VFM. These employees were not deemed employees of the Company, and VFM was responsible for the payment and provision of all wages, bonuses, commissions and benefits. Reimbursable salaries paid to VFM were approximately $180,000 during the year ended December 31, 2023. This agreement was terminated on September 29, 2023.

In December 2022, Velocity Fund Partners, LP, an affiliate of shareholders' of the Company invested $150,000 in a simple agreement for future equity issued by the Company.

On March 17, 2023, as amended on May 12, 2023 and August 29, 2023, the Company entered into the Business Combination under which the Company entered into a reverse takeover transaction ("RTO") with SkinJect